Among them, EP26 displayed the highest inhibitory activity, promoting cell death in vitro and inhibiting tumor growth in vivo, associated with increased CD4+ and CD8+ T cells in TME, which was more effective than gefitinib and PD‐L1 inhibitor P19. This evidence concerns the gene CD4 and neoplasm.